Pfizer sets August 4 earnings webcast, shares tied to upcoming NYSE update

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-23, 20:43.

Pfizer Inc. (US7170811035) has invited investors to a webcast and analyst conference call on August 4, 2026. The NYSE-listed S&P 500 component plans to discuss its second quarter 2026 results at 10:00 a.m. EDT in New York, according to its latest investor relations announcement. The Pfizer IR schedule outlines the August 4 analyst call and webcast

What Pfizer has scheduled

The company states that its second quarter 2026 performance report will be published on August 4, 2026, ahead of the webcast with analysts that morning. The webcast is set for 10:00 a.m. EDT, with dial-in numbers 800-456-4352 in the US and Canada and 785-424-1086 internationally, using passcode 29301. Pfizer’s Business Wire press release details the Q2 2026 webcast logistics

Pfizer plans to post the full second quarter 2026 performance report on its investor website the same morning, giving NYSE and global investors a detailed look at revenue, earnings and pipeline metrics. The company intends to provide a replay of the call and transcript on its website for at least 90 days after the event, making the information accessible beyond the live session.

Analyst consensus on the Pfizer shares

Consensus data compiled by Investing.com shows that 27 analysts currently cover the Pfizer shares, with a "Buy" rating on average. Within this group, 11 analysts recommend buying, 16 rate the stock as a hold and 2 see it as a sell, according to the latest consensus overview. Investing.com’s Pfizer consensus page summarizes these analyst ratings and targets

The same consensus places the average 12-month price target around 29.19 US dollars, with estimates ranging from 24 US dollars at the low end to 36 US dollars at the high end. With the shares recently trading in the mid-20s on the NYSE, the implied upside from the average target is calculated at roughly 17 percent, based on the Investing.com data set.

The medicines behind the Pfizer stock

Pfizer generates a substantial portion of its revenue from cardiovascular and metabolic therapies, including Eliquis, which it co-markets with Bristol Myers Squibb for stroke prevention in patients with atrial fibrillation. The group also remains active in vaccines, oncology and immunology, where late-stage pipeline decisions can shift the medium-term earnings trajectory.

Where the Pfizer shares trade today

The Pfizer shares (US7170811035) most recently traded on the NYSE at about 24.75 US dollars on June 23, 2026, in a session that MarketBeat data show ended with a 1.32 percent decline for the day.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data are based on sources deemed reliable but cannot be guaranteed. Investors should conduct their own research or consult a professional advisor before making investment decisions.